Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

NCT04225312 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT04225312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04225312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 4
Overall status
Unknown status
Start date
February 3, 2020
Completion date
March 1, 2025
Enrollment
300 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis